Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Healthy
Interventions: SPY002-091, Placebo; Drug · Other
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers
Interventions: TAK-418, [18F]MNI-1054 (radiotracer); Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab); Drug · Other · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: PAH Therapies; Other
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Brandon, Florida • Tampa, Florida • Chicago, Illinois + 12 more

Conditions: Acute Myeloid Leukemia
Interventions: Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 36
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 28 more

Conditions: Nicotine Dependence, Smoking
Interventions: N-acetylcysteine (NAC), Placebo; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic Syndrome Acute Myeloid Leukemia
Interventions: Nivolumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Mental Health Issue, COVID-19
Interventions: in person meditation, in person meditation using headphones, virtual meditation; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Mitapivat tablets, Mitapivat coated granules; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis (RA)
Interventions: Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 63 more

Conditions: Parkinson Disease, Healthy Aging
Interventions: Cognitive dual-task walking; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 60 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Coronary Artery Disease, Ischemia
Interventions: Computed Tomography Angiography; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Low Back Pain
Interventions: tDCS, Lidocaine cream, Control cream; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Pediatric Pre-operative Stress
Interventions: Relaxing Music, No Music; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 10 Years to 16 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Breast Neoplasms
Interventions: Abemaciclib, Tersolisib, Letrozole, Anastrozole, Exemestane; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Los Alamitos, California • Lakewood, Colorado • Atlanta, Georgia + 6 more

Conditions: Burns
Interventions: ReCell and Split-thickness skin graft; Device
Lead sponsor: Avita Medical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 9 more

Conditions: Pneumococcal Infection
Interventions: V110, V114, mRNA-1273, Placebo for V110, Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 42
States / cities: North Hollywood, California • Northridge, California • Paramount, California + 38 more

Conditions: Anemia, Chronic Kidney Disease
Interventions: AKB-6548, Placebo; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more

Conditions: Acute Gouty Arthritis Flares
Interventions: ACZ885, Triamcinolone acetonide 40 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Anniston, Alabama • Mobile, Alabama • Norwalk, California + 28 more

Conditions: Autism Spectrum Disorder, Autism
Interventions: Virtual Reality Intervention, Video Modeling Intervention, No intervention; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Years to 60 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mild Cognitive Impairment, Healthy Aging
Interventions: RFB, VSOP, IR; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years to 89 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy Adult Immune Response
Interventions: VRC-HIVMAB095-00-AB (10E8VLS), VRC-HIVMAB075-00-AB (VRC07-523LS); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obsessive-Compulsive Disorder
Interventions: Exposure and Response Prevention Therapy, Clinical Assessments, Research MRI Sessions; Behavioral · Other · Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 10 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions: CPX-351; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

A Study of SPY002-091 in Healthy Volunteers

A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

N-acetylcysteine for Tobacco Use Disorder

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Music Mindfulness Study 2a.

A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants

Methotrexate-Inadequate Response Study

Longitudinal Analysis of Gait Variability to Predict Falls in Parkinson's Disease

Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease

Neuromodulation of Lidocaine Cream Effect on Chronic Pain Patients

Pre-operative Stress Reduction With Music

A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer

A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

VR Intervention to Improve Police Safety

Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

Precision Brain Mapping to Predict and Track Response to Exposure and Response Prevention Therapy in Youth With Obsessive-Compulsive Disorder

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia